IBRX - What's Going On With ImmunityBio Stock? | Benzinga
ImmunityBio, Inc. (NASDAQ:IBRX) shares are trading higher Friday after the company announced overall survival results in its QUILT 3.055 study.
The Details:
ImmunityBio said the QUILT 3.055 trial shows median overall survival almost double that of standard of care chemotherapy in 2nd- and 3rd-line non-small cell lung cancer (NSCLC) patients whose cancer did not respond to checkpoint inhibitors with or without chemotherapy.
"The results we noted with the completion of the QUILT 3.055 basket trial across multiple tumor types in patients with late-stage cancers for whom standard of care plus checkpoints failed, validates our hypothesis that orchestration of NK cells with killer T cells and memory T cells could result in meaningful clinical improvements to current standards of care," said Patrick Soon-Shiong, M.D., CSO of ImmunityBio.
The FDA approved the ...